Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: A multicentre randomised trial

Journal of Hepatology

Volumn 29, Issue 2, 1998, Pages 224-232

  Degos, Françoise ^a   Daurat, Véronique ^j   Chevret, Sylvie ^b   Gayno, Sophie ^c   Bastie, Anne ^d   Riachi, Ghassan ^e   Bartolomei Portal, Isabelle ^f   Barange, Karl ^g   Moussalli, Joseph ^h   Naveau, Sylvie ^j   Bailly, François ⁱ   Chaumet Riffaud, Philippe ^j   Chastang, Claude ^b  

^a BEAUJON HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c CENTRE HOSPITALIER RENÉ DUBOS   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e HÔPITAL CHARLES NICOLLE   (France)

^f HÔPITAL DE LA CONCEPTION   (France)

^g CHU PURPAN   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ HÔTEL DIEU   (France)

^j NONE

more..

Author keywords

Chronic hepatitis; Interferon a; Randomised trial

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2A INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032147073     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80007-X     Document Type: Article

References (31)

1. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 332:1995;1463-1466.
2. Tine F, Magrin S, Craxi A, Pagliaro L. Inteferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol. 13:1991;192-199.
3. Poynard T, Leroy V, Cohard M, Thévenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 24:1996;778-789.
4. Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, et al. High doses of recombinant α interferon or γ interferon for chronic hepatitis C: a randomised controlled trial. Hepatology. 13:1991;327-331.
5. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomised multicentre trial. Hepatology. 24:1996;1034-1040.
6. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. Randomised trial comparing three differnt regimens of alpha 2a interferon in chronic hepatitis C. Hepatology. 22:1995;700-706.
7. Rumi M, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, et al. A prospective randomised trial comparing lymphoblastoid to recombinant interferon alpha 2a as therapy for chronic active hepatitis C. Hepatology. 24:1996;1366-1370.
8. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alpha 2b regimens for the long term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 332:1995;1457-1462.
9. Dhumeaux D, Doffoel M, Galmiche JP. A French consensus conference on hepatitis C: screening and treatment. J Hepatol. 27:1997;941-944.
10. National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology. 26:1997;2-10. (suppl 1).
11. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high dose interferon α-2b. Dig Dis Sci. 38:1993;612-618.
12. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
13. Fried MW, Hoofnagle JH. Therapy of chronic hepatitis C. Semin Liver Dis. 15:1995;82-91.
14. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Oshita M, et al. Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J Hepatol. 22:1995;457-463.
15. Enomoto N, Sakuma I, Asahima Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutation in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 334:1996;77-81.
16. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM. and le groupe français pour l'étude du traitement des hépatites NANB/C. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology. 106:1994;686-690.
17. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al. Long term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 111:1996;1307-1312.
18. Reichen J, Bianchi L, Bühler H, Dolivo N, Gonvers JJ, Lavanchy D, et al. Fixed versus titrated interferon α-2b in chronic hepatitis C. A randomised controlled multicentre trial. J Hepatol. 25:1996;275-282.
19. Magrin S, Craxi A, Fabiano C, Marino L, Fiorentino G, Lo Iacono, et al. HCV viraemia is more important than geno-type as a predictor of response to interferon in Sicily. J Hepatol. 25:1996;583-590.
20. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH, et al. Epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med. 125:1996;634-639.
21. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. for the Australian Hepatitis C Study Group. Interferon alfa 2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol. 23:1995;487-496.
22. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, et al. Long term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon α therapy. Ann Intern Med. 127:1997;875-881.
23. Roffi L, Mels GC, Antonelli G, Bellati G, Panizzuti F, Piperno A, et al. Breakthrough during recombinant interferon alpha therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology. 21:1995;645-649.
24. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicentre randomised controlled trial. Hepatology. 21:1995;291-297.
25. Pawlotsky JM, Roudot-Thoraval F, Bastie A, Darthuy F, Remire J, Metreau J, et al. Factors affecting treatment responses to interferon-α in chronic hepatits C. J Infect Dis. 174:1996;1-7.
26. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long term pathological evolution of chronic hepatitis C. Hepatology. 23:1996;1334-1340.
27. Ziol M, Tran Van Nhieu J, Roudot-Thoraval F, Métreau JM, Deugnier Y, Dhumeaux D, et al. A histopathological study of the effects of 6-month versus 12-month interferon α-2b therapy in chronic hepatitis C. J Hepatol. 25:1996;833-841.
28. Poynard T, Bedossa P, Opolon P. for the OBSVIR, METAVIR, CLINVIR, and DOSVIR groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 349:1997;825-832.
29. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparisons of 1 or 3 MU of interferon alfa 2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 101:1991;497-502.
30. Schiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C. Hepatology. 26:1997;780-785.
31. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol. 26:1997;1187-1199.